Fulcrum Therapeutics (FULC) Earnings Date & Reports
Get AI intraday signals
A.I. Advisor
published Earnings
FULC is expected to report earnings to fall 18.91% to -28 cents per share on February 27
Q4'24
Est.
$-0.28
Q3'24
Beat
by $0.05
Q2'24
Beat
by $1.28
Q1'24
Beat
by $0.01
Q4'23
Beat
by $0.03
The last earnings report on November 13 showed earnings per share of -34 cents, beating the estimate of -40 cents. With 287.56K shares outstanding, the current market capitalization sits at 244.88M.
a clinical-stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies.